Literature DB >> 9118522

Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis.

M Hernández-Presa1, C Bustos, M Ortego, J Tuñon, G Renedo, M Ruiz-Ortega, J Egido.   

Abstract

BACKGROUND: The migration of monocytes into the vessel wall is a critical event leading to the development of atherosclerosis. Monocyte chemoattractant protein-1 (MCP-1) is the main chemotactic factor involved in this phenomenon, and nuclear factor-kappa B (NF-kappa B) is one of the nuclear factors controlling its expression. ACE inhibitors have been useful in some experimental models of atherosclerosis. In this work, we addressed the hypothesis that angiotensin II (Ang II) may be implicated in the recruitment of monocytes into the vessel wall through the activation of NF-kappa B and the induction of MCP-1 expression. METHODS AND
RESULTS: Accelerated atherosclerosis was induced in the femoral arteries of rabbits by endothelial desiccation and atherogenic diet for 7 days. Atherosclerotic vessels exhibited an increase in NF-kappa B-like activity, and p50 and p65 NF-kappa B subunits were identified as components of this activity. MCP-1 (mRNA and protein) was also expressed in the injured vessels coincidently with the neointimal macrophage infiltration. ACE inhibition with quinapril reduced these three parameters. In cultured monocytic and vascular smooth muscle cells. Ang II elicited an increase in NF-kappa B activation and MCP-1 expression that was prevented by preincubation of cells with pyrrolidinedithiocarbamate, an inhibitor of NF-kappa B activation.
CONCLUSIONS: The present data support a role for Ang II in neointimal monocyte infiltration through NF-kappa B activation and MCP-1 expression in a model of accelerated atherosclerosis in rabbits. Our results suggest that ACE inhibitors may have a beneficial effect in early atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9118522     DOI: 10.1161/01.cir.95.6.1532

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  84 in total

1.  Interaction between blood pressure, lipoproteins, angiotensin, and vascular disease.

Authors:  Aram V Chobanian
Journal:  Curr Hypertens Rep       Date:  2002-04       Impact factor: 5.369

Review 2.  Clinical implications of matrix metalloproteinases.

Authors:  Malay Mandal; Amritlal Mandal; Sudip Das; Tapati Chakraborti; Chakraborti Sajal
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

Review 3.  Effects of angiotensin converting enzyme inhibitors on thrombotic mediators: potential clinical implications.

Authors:  Seema A Kothari; Mytrang K Le; Pritesh J Gandhi
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

4.  Coronary artery disease, inflammation and the ghost of John Hunter.

Authors:  Ernest L Fallen
Journal:  Inflammopharmacology       Date:  2003       Impact factor: 4.473

Review 5.  Monocyte chemoattractant protein-1: a key mediator of angiotensin II-induced target organ damage in hypertensive heart disease?

Authors:  Jia L Zhuo
Journal:  J Hypertens       Date:  2004-03       Impact factor: 4.844

Review 6.  Monocytes as immune targets in arterial hypertension.

Authors:  Philip Wenzel
Journal:  Br J Pharmacol       Date:  2018-07-14       Impact factor: 8.739

Review 7.  Immunologic Effects of the Renin-Angiotensin System.

Authors:  Steven D Crowley; Nathan P Rudemiller
Journal:  J Am Soc Nephrol       Date:  2017-02-01       Impact factor: 10.121

8.  Secreted protein acidic and rich in cysteine deficiency ameliorates renal inflammation and fibrosis in angiotensin hypertension.

Authors:  Matthew J Socha; Marlina Manhiani; Neveen Said; John D Imig; Kouros Motamed
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

9.  Effect of two phenanthrene alkaloids on angiotensin II-induced leukocyte-endothelial cell interactions in vivo.

Authors:  Rossana Estellés; Javier López-Martín; Lara Milian; José-Enrique O'Connor; Magdalena Martínez-Losa; Miguel Cerdá-Nicolás; Edet M Anam; María Dolores Ivorra; Andrew C Issekutz; Julio Cortijo; Esteban J Morcillo; Maria Amparo Blázquez; Maria-Jesús Sanz
Journal:  Br J Pharmacol       Date:  2003-10-14       Impact factor: 8.739

Review 10.  The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies.

Authors:  Fabrizio Montecucco; Aldo Pende; François Mach
Journal:  Mediators Inflamm       Date:  2009-04-14       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.